CD73 Expression as a Potential Marker of Good Prognosis in Breast Carcinoma

Supernat, Anna; Markiewicz, Aleksandra; Wełnicka-Jaśkiewicz, Marzena; Seroczyńska, Barbara; Skokowski, Jarosław; Sejda, Aleksandra; Szade, Jolanta; Czapiewski, Piotr; Biernat, Wojciech; Żaczek, Anna

doi:10.1097/pai.0b013e3182311d82

Cited by 76 publications

(73 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Multivariate analysis for disease-free survival revealed correlation with tumor size and CD73 status. Elevated CD73 expression in breast cancer can predict a good prognosis by the Kaplan-Meier method (22). Therefore, CD73 plays an important role in tumor promotion, while the mechanisms by which this occurs have remained elusive.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Potential prognostic biomarker CD73 regulates epidermal growth factor receptor expression in human breast cancer

Zhi

Wang

et al. 2012

IUBMB Life

View full text Add to dashboard Cite

SummaryCD73, an ecto-enzyme overexpressed in breast-cancer cells, catalyzes the dephosphorylation of adenosine monophosphates into adenosine. Anti-CD73 slows breast cancer growth and its spread both in vivo and in vitro. In this study, we investigated the relation of CD73 to epidermal growth factor receptor (EGFR) expression using tissue array and breast cancer cell lines. We found that CD73 expression correlated positively to EGFR expression in vivo (n 5 80, r 5 0.425, P \ 0.01) and in vitro. EGFR expression can be decreased by suppressing CD73 with an inhibitor or small shRNA, and this effect was reversed by adenosine and NECA (adenosine A2 receptor agonist), which suggested that adenosine is involved in EGFR expression regulated by CD73 (P \ 0.01). We also showed that CD73 regulates EGFR phosphorylation by Src (P \ 0.01). By transcription factor (TF) assay, CD73 was found to regulate some associated TFs activity such as PPARc, which mediates EGFR expression, although whether PPARc mediates the effect of CD73 on EGFR expression needs further study. The KaplanMeier recurrence-free survival curves for CD73 were also plotted in www.kmplot.com. The curves show that CD73 expression separates the cases into significantly different prognostic groups among the estrogen receptor-negative cancers (P \ 0.01). Our results suggest that CD73 may be a potential prognostic biomarker associated with coexpression of EGFR in human breast cancer.2012 IUBMB IUBMB Life, 64(11): 911-920, 2012

show abstract

Section: Discussionmentioning

confidence: 99%

“…Supernat et al (22) reported that elevated CD73 expression in breast cancer can predict a good prognosis by the KaplanMeier method. To validate CD73 as a prognostic candidate gene, we replotted the Kaplan-Meier recurrence-free survival curves for CD73 in www.kmplot.com.…”

Section: Discussionmentioning

confidence: 99%

Potential prognostic biomarker CD73 regulates epidermal growth factor receptor expression in human breast cancer

Zhi

Wang

et al. 2012

IUBMB Life

View full text Add to dashboard Cite

show abstract

“…Supernat et al showed that elevated CD73 expression in breast cancer can predict a good prognosis of the disease [26]. In addition, Zhi et al suggested that CD73 may be used as a potential prognostic & therapeutic biomarker for breast cancer [27].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of tissue 5´-Nucleotidase as tumor marker in breast and brain tumors using receiver operating characteristic curve

Hr¹,

Th²,

Me³

2013

J Cancer Res Ther

View full text Add to dashboard Cite

“…CD73 was initially identified as a cell surface antigen that was specific to hematopoietic stem cells and functioned in a number of physiological processes in various normal human tissues, including hypoxic adaptation, ischemic preconditioning and inflammation (15)(16)(17). CD73 is reportedly activated in aggressive breast cancer, gastric and pancreatic cancers and lymphoma, and may be used as a prognostic marker for these tumors (18,19). The protective role of CD73 in renal ischemia (20) and the absence of tubuloglomerular feedback responses in CD73-deficient mice (14) have indicated the important role of CD73 in the function of renal tissue.…”

Section: Introductionmentioning

confidence: 99%

“…However, the role of CD73 expression in cancer cells in determining the prognosis of patients remains controversial in breast cancer (29,(38)(39)(40), which may be due to the conversion of adenosine that is promoted by CD73 in tumors. In the present cohort of RCC patients, intense CD73 protein expression in cancer cells was associated with a Inf lammator y hypoxia (14), hypoxia inducible factor-1 (HIF-1) (41) and Wnt signaling (42,43) are potent transcriptional stimuli for CD73 expression, which implies that the microenvironment of malignant tumors elevates CD73 expression.…”

mentioning

confidence: 99%

Ecto-5′-nucleotidase expression is associated with the progression of renal cell carcinoma

Wang

Song

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. Renal cell carcinoma (RCC) is a common tissue tumor that occurs across all age groups and has become one of the types of cancer with the fastest increasing incidence. Due to the resistance of RCC chemo-and radiotherapy, surgery is the only currently effective treatment. Therefore, specific markers for the diagnosis and prognosis of RCC are expected to result in novel methods of treatment. Ecto-5'-nucleotidase, also termed cluster of differentiation (CD)73, is a protein that is activated in several types of aggressive cancer and may promote cancer progression. CD73 was examined in the present study to determine the association between the protein and RCC. The expression levels of CD73 in 159 RCC tissue sections and 30 paratumorous normal renal tissue samples obtained from 235 patients that underwent nephrectomy were examined by immunohistochemical staining. By contrast, the expression level of P-glycoprotein (P-gp), a potential prognostic factor in RCC, was also examined in 85 RCC and 13 normal tissue samples. Intense CD73 expression was identified in 75 out of 159 RCC cell membranes compared with normal renal tissues. In contrast, there was high P-gp expression in the blood vessels of 42 out of 85 RCC tissues and there was no significant difference between the P-gp expression identified in RCC cells (34 out of 85) and the cell membrane of normal renal cells (2 out of 13). The expression level of CD73 in RCC cells was significantly associated with tumor type, tumor node metastasis (TNM) stage, and tumor grade. However, the expression of P-gp in RCC cells was only associated with the TNM stage and tumor grade. Using a multivariable Cox regression analysis, it was found that the median survival rate of RCC patients with intense CD73 expression in RCC cells was 62.06±5.35 months, which was drastically shorter compared with rare CD73 expression (103.72±3.67 months). In conclusion, the expression level of CD73 is significantly associated with RCC tumor progression and may serve as a favorable marker for the diagnosis and prognosis of RCC, in addition to being a therapeutic target for the treatment of RCC.

show abstract

CD73 Expression as a Potential Marker of Good Prognosis in Breast Carcinoma

Cited by 76 publications

References 16 publications

Potential prognostic biomarker CD73 regulates epidermal growth factor receptor expression in human breast cancer

Potential prognostic biomarker CD73 regulates epidermal growth factor receptor expression in human breast cancer

Evaluation of tissue 5´-Nucleotidase as tumor marker in breast and brain tumors using receiver operating characteristic curve

Ecto-5′-nucleotidase expression is associated with the progression of renal cell carcinoma

Contact Info

Product

Resources

About